An interventional study of nasopharyngeal sample (mandatory) and Stools collection or anorectal swab samples (optional) in Nasopharyngeal Carriage, Children, Only and Antibiotic Resistant Strain, sponsored by Association Clinique Thérapeutique Infantile du val de Marne. Recruiting at 1 site in France. Open to participants aged 4 Months to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Association Clinique Thérapeutique Infantile du val de Marne · Not applicable, Interventional, and Other
Cohen R, Bidet P, Varon E, Bechet S, Cohen JF, Bonacorsi S, Levy C. Unprecedentedly high rates of Group A Streptococcus nasopharyngeal carriage in infants and…PubMed 37196808 ↗; 1 more
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Sprains and Strains with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Sprains and Strains · France.
Among the 29 studies in Sprains and Strains with a site in France, this one has the largest planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2001, is one of 11 with no phase, and was the 15th registered.
246 studies on the registry are indexed under Sprains and Strains; 49 are open to participants now.
Browse Sprains and Strains studies →7 of the 29 studies in Sprains and Strains with a site in France are open now. Recruiting first, the newest first:
University Hospital, Angers · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Healthy volunteers
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Association Clinique Thérapeutique Infantile du val de Marne · Sites in France
Ages 1 days–17 yrs
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 36 Sprains and Strains studies recruiting now, 13 (36%) set no upper age limit and 20 (56%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 4 Months to 15 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 29,360 is above the median of 60 across 162 interventional studies indexed under Sprains and Strains.
Median enrollment 64 across the 13 interventional studies, 101 across the 16 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 29 have an industry lead sponsor. The 10 most frequent:
Association Clinique Thérapeutique Infantile du val de Marne is the lead sponsor of 15 studies on the registry; 11 are open to participants now.
Association Clinique Thérapeutique Infantile du val de Marne has 2 studies filed under Sprains and Strains — fewer than ten, so there is no comparison to draw.
2 of the studies in Sprains and Strains with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07028476University Hospital, AngersNew Care Pathway Using Automated Dynamic Laximetry | 2027-03 |
| NCT06009731Centre Hospitalier Universitaire, AmiensDiaphragmatic Speckle Tracking During Spontaneous Breathing Trial | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Sprains and Strains with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in 2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae serotypes in children with acute otitis media and modified the resistance of this bacterial species to antibiotics.
Since September 2001, 66 pediatricians from the ACTIV research and teaching network throughout France participate in this prospective study. Each year from October to June, children of both sexes aged 4 to 36 months, presenting with suppurative acute otitis media (AOM) accompanied by fever and/or otalgia (to increase the probability of pneumococcal AOM), are enrolled. Within this cohort, patients are offered an additional, optional nasal swab for a rapid viral diagnostic test (targeting SARS-CoV-2, RSV, Influenza A, Influenza B, and hMPV).
Additionally, another group of healthy children aged 4 months to 15 years is also enrolled for the main study.
For the ancillary study, a subgroup of children with AOM (aged 6 to 24 months) is enrolled for the assessment of ESBL-producing E. coli resistance.
The criteria were revised on the registry on Oct 27, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
children seen on an outpatient
Inclusion Criteria:
suffering from suppurative AOM or healthy children
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2100 children aged 4 to 36 months with AOM and 1500 healthy control children aged 4 months to 15 years will be enrolled. A mandatory nasopharyngeal swab is planned for these groups.
Other: nasopharyngeal sample (mandatory)
For a subgroup of approximately 1500 children with AOM, aged 6 to 24 months, optional stool or anorectal swab samples will be collected.
Other: nasopharyngeal sample (mandatory) · Other: Stools collection or anorectal swab samples (optional) · Other: nasopharyngeal sample (optional)
For a subgroup of 1680 children with AOM, an optional nasal sample will be collected to assess the association of various respiratory viruses (SARS-CoV-2, RSV, Influenza A, Influenza B, hMPV) with different pneumococcal serotypes.
Other: nasopharyngeal sample (mandatory) · Other: nasopharyngeal sample (optional)
A mandatory nasopharyngeal swab is planned for each included patient: patients aged 4 to 36 months with AOM and control children (healthy) aged 4 months to 15 years. The bacteriological analyses will be carried out by the French National Reference Centre for Pneumococci.
For a subgroup of AOM children aged 6 to 24 months, stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
Optional nasopharyngeal swabs from children with AOM aged 4 to 36 months to assess the association of various respiratory viruses (SARS-CoV-2, RSV, Influenza A, Influenza B, hMPV) with different pneumococcal serotypes.
S. Pneumoniae colonisation
Percentage of children colonised by S. Pneumoniae
Time frame: at inclusion
S. Pneumoniae colonisation involving to vaccine serotypes
Percentage of children colonised by vaccine serotypes
Time frame: at inclusion
S. Pneumoniae colonisation involving to non vaccine serotypes
Percentage of children colonised by non vaccine serotypes
Time frame: at inclusion
Reduced of sensitivity to penicillin
Percentage of Sp carriers with reduced sensitivity to penicillin
Time frame: at inclusion
Detect the emergence of new serotypes
Percentage of emerging serotypes detected (\> 10 Percent of isolated Sp, 5 percent of carrier children)
Time frame: at inclusion
Association of Pneumococcal Serotypes with Respiratory Viruses
Percentage of pneumococcal serotypes associated with various respiratory viruses (SARS-CoV-2, RSV, Influenza A, Influenza B, hMPV) in children with AOM.
Time frame: at inclusion
Detect the emergence of resistance S. pneumoniae
Percentage of penicillin resistant S. pneumoniae
Time frame: at inclusion
Evaluation of nasopharyngeal carriage of other bacteria
Assessment of carriage of Haemophilus influenzae, Moraxella Catarrhalis, Staphylococcus aureus and group A Streptococcus in AOM group and in healthy children group.
Time frame: at inclusion
For the ancillary study, the resistance of E. coli (ESBL) will be evaluated.
Assessment of E. coli (ESBL) resistance.
Time frame: at inclusion
Plan to share: No
Started Sep 2001 (actual). Primary completion is estimated for Dec 2029, 339 months after the start.
Of 80 non-industry interventional studies with no phase under Sprains and Strains, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 35. This study's planned 339 months is above that.
Counting every sponsor, half of 82 studies reached it within 12 months; a quarter within 4 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2026 → Dec 2029 and completion Dec 2026 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Cohen R, Bidet P, Varon E, Bechet S, Cohen JF, Bonacorsi S, Levy C. Unprecedentedly high rates of Group A Streptococcus nasopharyngeal carriage in infants and…PubMed 37196808 ↗; 1 more
Cohen R, Bidet P, Varon E, Bechet S, Cohen JF, Bonacorsi S, Levy C. Unprecedentedly high rates of Group A Streptococcus nasopharyngeal carriage in infants and…PubMed 37196808 ↗; 1 more
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Association Clinique Thérapeutique Infantile du val de Marne